Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23253764.
- Also identified by DOI 10.1016/j.amepre.2012.09.045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
During the past few years, much has been learned about pre-exposure prophylaxis (PrEP) of HIV from studies conducted in the U.S. and elsewhere. A review and summary was conducted of articles and reports published through August 2012 on the safety and efficacy of PrEP in humans; U.S.-based studies assessing PrEP knowledge, attitudes, and use among at-risk populations and healthcare providers; and models of the cost effectiveness of PrEP. PrEP is generally safe and effective and may be cost effective in a targeted population. Awareness and interest in PrEP are increasing. PrEP is an important new addition to HIV prevention services, but continued study is warranted.
Medical subject headings
- Anti-HIV Agents
- Clinical Trials as Topic
- HIV Infections